Mutations in the intracellular juxtamembrane domain of the c-kit gene in 32 dogs with different grades of histologically confirmed mastocytoma were studied. Transcript RNAs extracted from neoplastic tissue surgically collected from dogs of different breeds and from a negative control were reverse transcribed into complementary DNA and amplified by polymerase chain reaction. The region corresponding to the c-kit juxtamembrane domain was sequenced and compared with GenBank sequences. Two different types of mutations were identified within exon 11: a previously underscribed single-nucleotide substitution and a 6-bp deletion. The c-kit juxtamembrane domain sequences of all dogs were grouped in 3 clusters. No mutations were detected in tissues constitutively expressing c-kit (cerebellum and spleen), obtained from dogs not affected by mastocytoma (controls). All the substitutions were found in dogs bearing grade I or II mast cell tumors; the deletion was detected in 1 dog with grade II mastocytoma.
Mast cell tumors or mastocytomas are some of the most frequently diagnosed skin neoplasms in dogs, accounting for 16-21% of all skin tumors and 11-27% of all malignant skin tumors. Most mastocytomas arise from the dermis and subcutaneous tissues; widely disseminated mastocytosis is not common (less than 10% of cutaneous cases). 7 The biological behavior of mastocytomas is highly variable; some tumors have benign behavior, whereas others have aggressive growth and metastasize. 2 A number of different parameters have been described as predictors of the clinical behavior of canine mastocytoma, the most consistent of which are histologic grade and clinical stage. 6 In recent years, molecular parameters have received more focus.
The proto-oncogene c-kit, encoding the transmembrane c-kit protein (KIT) receptor, is known to play a From critical role in development of mast cell tumors. 5 Two mechanisms have been proposed for mast cell proliferation: ligand dependent and ligand independent. 1 One of the mechanisms proposed for the ligand-independent mast cell proliferation in dogs is the alteration of the nucleotide sequence of the c-kit gene within the juxtamembrane domain. 4 The aim of this study was to identify the types and locations of c-kit mutations in a large number of canine mastocytomas, with a view to establishing correlations between c-kit mutations and histological classification or clinical features, or both. 6 Moreover, the authors were interested in verifying whether such mutations could be used as a diagnostic or prognostic tumor marker for mastocytoma.
The mutational status of the c-kit region encompassing exons 9-13 was evaluated in a heterogeneous population of 32 spontaneous canine mastocytoma cases that were followed up for over a year. Abnormal masses were detected by clinical examination. Clinical signs of cutaneous mastocytomas included firm, elevated, circumscribed, often swollen, or ulcerated lesions of the dermis from less than 1 cm to greater than 10 cm in diameter. The area appeared to be alopecic and erythematous in a few cases. Figure 1 shows 1 case of a mastocytotic cutaneous lesion. Information on age, breed, sex, clinical signs, laboratory examinations, time from the first admission, and treatments was obtained from the medical records of each patient. All dogs underwent surgical excision of the entire tumor, and the diagnosis was confirmed by histological examination. On the basis of histopathological findings, the tumors were categorized as grade I in 11 dogs, grade II in 14 dogs, and grade III in 5 dogs. No histopathologic results were obtained from 2 dogs. In addition, samples from the spleen and cerebellum (tissues constitutively expressing c-kit) were removed from a non-tumor-bearing dog immediately after euthanasia (control tissues). Fourteen of the patients underwent chemotherapy with lomustine, prednisone, vinblastine, vincristine sulfate, or cyclophosphamide after surgical excision; 1 was treated with radiation therapy. During the follow-up period, 7 patients died of diseases unrelated to the tumors, 4 were euthanized because of progressive debilitating disease, and 21 patients remained healthy.
Extraction of total RNA was performed on fresh biopsy tumor tissue surgically collected from each dog. The specimens were obtained from the central part of the tumor mass, carefully avoiding margins and nonneoplastic surrounding tissue. Each specimen was minced into small pieces and handled under sterile conditions. Extraction of total RNA was performed using 6100 Prep Station and Reagents a on the tissues after complete homogenization with a rotor/stator system. a The purified mRNA was reverse transcribed into complementary DNA (cDNA) using the cDNA Retrotranscription Archive kit with random hexamers. b The cDNA obtained from each sample was amplified by polymerase chain reaction (PCR) in a 50-l reaction volume containing 20 l of template cDNA, 2 M of each primer, 0.25 U Platinum Taq DNA polymerase, 5 l of the corresponding 10ϫ reaction buffer, 1.5 mM MgCl 2 , and 250 M of each deoxynucleoside triphos-phate, completed by sterile water. b The PCR was carried out for 30 cycles of 1 minute at 95 C for denaturation, 1 minute at 55 C for annealing, and 1 minute at 72 C for elongation. The primers used for this PCR were 5Ј-CTTCAAGCACAATGGCACAGTC-3Ј (forward primer nt 1480-1501) and 5Ј-AGCATCTTA-ACGGCAACAGTCA-3Ј (reverse primer, nt 1875-1896). The primer sequences were derived from the published canine cDNA c-kit sequence (accession No. gi:32351485 gb:AY313776.1) in the GenBank database. The c-kit gene-amplified sequence of 416 bp included most of the juxtamembrane domain, corresponding to part of exon 9, exons 10, 11, 12, and a few nucleotides of exon 13. The amplified c-kit DNAs were purified from agarose gel using QIAquick PCR purification kit reagents c and custom sequenced in both directions using the primers listed above. All the nucleotide sequences were aligned with BioEdit version 5.0.9 Software 3 to identify the mutations, using the wild-type sequence as baseline. All the complete canine c-kit sequences available in GenBank (gi: 31580770, gi:4731158, gi:17530527, gi:4105259) were aligned to detect common mutations or possible polymorphisms. TREECON Software for Windows version 1.3b 8 was used for clustering.
The following breeds were represented among the affected dogs: Boxer, Setter, Beagle, Labrador, Rottweiler, Schnauzer, American Terrier, Pincher, Briard, German shepherd, and mix-breeds. Mix-breed dogs accounted for 30% (11 of 32) of cases. Eighteen dogs were males, 14 were females. Median age was 9 years, with a range of 7-14 years, except for 5 animals that ranged from 2.5 to 5 years of age. Tumor locations included the trunk, the head/neck region, the mammary gland region, the perineal region, and the extremities.
Details on the different types of nucleotide mutations are given in Fig. 2 . All the detected mutations resided in exon 11, which has been reported to be the region containing the majority of mutations. 4 These included only grade I or II mastocytomas. The most common type of mutation was a point substitution of C with T at position 1756 (22% of cases). This mutation has not been described before. A 6-bp deletion (1691-1696) eliminating Trp-556 and Lys-557 was present in 1 case (19) with a grade II tumor. Figure 3 shows the tree representing the cases grouped with the TREECON Software, 8 based on the c-kit nucleotide sequences. The negative controls (non-tumor-bearing dog's cerebellum and spleen) did not show any molecular alteration.
A hallmark in understanding the biology of mast cell tumors is the detection of gain/loss-of-function mutations in the gene encoding the KIT receptor, which represents a transmembrane type III receptor for tyrosine kinase. The majority of these mutations have been found in exon 11 encoding the juxtamembrane domain. London et al. 4 detected tandem duplications and Ma et al. 5 found deletions and substitutions in exons 11 and 12, which induce constitutive activation of the KIT receptor. 4, 5 The aim of this study was to further examine whether mutations in the c-kit gene, which are implicated in the pathogenesis of canine mastocytoma, could be used as a marker for diagnosis and prognosis. It is still not clear whether the location and type of c-kit mutation rather than the presence of a mutation per se might be of significance for tumor behavior. The results of this study appear to point to an association between the presence of c-kit mutations in the juxtamembrane domain and the development of malignancy. However, a larger number of cases would need to be studied to confirm such an association.
Regarding breed predisposition, studies of the authors agree with other reports indicating that some breeds (Boxer, Beagle, and Setter) are more commonly affected, but no association was found between type of mutation and breed, sex, or age. Alterations in the juxtamembrane domain of c-kit gene may influence disregulation of KIT function and development of mast cell neoplasms in different ways. Because the juxtamembrane region directly interacts with the Nterminal ATP-binding lobe of the tyrosine kinase domain, a mutation in that region may disrupt the stability of this domain and alter its interaction with the functional site of the kinase. Because the KIT juxtamembrane region displays an inhibitory role in controlling the kinase receptor activity, mutations within this domain may result in ligand-independent activation of c-kit involving indirectly the catalytic domain. The outcome of such mutation-induced activation of KIT may be mast cell proliferation and mastocytoma development.
In conclusion, although not of prognostic value, the results of this study taken together suggest that in addition to traditional criteria, specific types of c-kit mutations in exon 11 per se might serve as a clinically useful parameter for mast cell tumor classification and perhaps development of targeted therapy. The complexity and molecular diversity of canine mastocytomas may explain the high variability of biological behavior of these tumors. Site-directed mutagenesis and functional studies of KIT are required to provide novel insights into the functional significance of each mutation and the development of therapeutic strategies that could lead to a complete cure; studies on substrate-binding specificities of KIT juxtamembrane mutants are essential to understand the molecular mechanisms underlying KIT signaling pathways for mast cell proliferative disorders. 
